Funding for this research was provided by:
Text and Data Mining valid from 2018-11-23
First Online: 23 November 2018
Compliance with Ethical Standards
: The AMAGINE-2/-3 studies were supported by Amgen. This analysis was supported by Ortho Dermatologics.
: Study protocols were consistent with the 2008 Declaration of Helsinki and the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines for Good Clinical Practice and were approved by individual institutional review boards at each participating study center. All participants signed and personally dated the informed consent form approved by the independent ethics committees and institutional review boards before any study-specific procedures were performed. Additional informed consent was obtained from all individual participants whose photographs appear in this article.
: Amy McMichael has been an investigator for Allergan, Casseopea, Concert, Incyte, and Samumed and a consultant to Aclaris, Galderma, IntraDerm, Johnson & Johnson, Merz, Pfizer, PharmaDerm, Procter & Gamble, and Samumed. Seemal R. Desai has been a consultant to Bausch Health Companies. Andrew F. Alexis has received grants from Dermira, Novartis, and LEO Pharma; consulting fees or honorarium from Novartis, LEO Pharma, and Bausch Health Companies; and speaking fees from LEO Pharma; and has provided writing assistance, medicines, equipment, or administrative support to Bausch Health Companies. Aamir Qureshi is an employee of Ortho Dermatologics and may hold stocks and/or stock options in Bausch Health Companies Pharmaceuticals. Shipra Rastogi may hold stocks and/or stock options in Bausch Health Companies Pharmaceuticals.
: The data that support the findings of this study are available from the corresponding author upon reasonable request.